Document Detail


The eosinophilic fasciitis syndrome after phenytoin (dilantin) therapy.
MedLine Citation:
PMID:  7441663     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A young woman with idiopathic temporal lobe epilepsy developed biopsy-proven oesinophilic fasciitis 16 months after the initiation of phenytoin therapy. Six months after withdrawal of this medication the fasciitis disappeared, and after 5 yr it has not recurred. This case highlights a possible association between the development of oesinophilic fasciitis and the use of medications such as phenytoin.
Authors:
R R Buchanan; D A Gordon; T J Muckle; F McKenna; G Kraag
Related Documents :
23369273 - Xenon in medical area: emphasis on neuroprotection in hypoxia and anesthesia.
3798263 - Advantages of the new low-osmolar radiographic contrast media.
21837893 - Physician, monitor thyself: professionalism and accountability in the use of social media.
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  The Journal of rheumatology     Volume:  7     ISSN:  0315-162X     ISO Abbreviation:  J. Rheumatol.     Publication Date:    1980 Sep-Oct
Date Detail:
Created Date:  1981-02-19     Completed Date:  1981-02-19     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7501984     Medline TA:  J Rheumatol     Country:  CANADA    
Other Details:
Languages:  eng     Pagination:  733-6     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Eosinophilia / chemically induced,  complications*
Epilepsy / drug therapy
Fascia / pathology
Fasciitis / chemically induced,  complications*
Female
Humans
Phenytoin / adverse effects*,  therapeutic use
Syndrome
Chemical
Reg. No./Substance:
57-41-0/Phenytoin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  SAA amyloid protein levels in amyloid-prone chronic inflammatory disorders. Lack of association with...
Next Document:  Interlaboratory salicylate variability.